Cancer Research 2010 AACR Elections Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kridel, S. J.
Right arrow Articles by Smith, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kridel, S. J.
Right arrow Articles by Smith, J. W.
[Cancer Research 64, 2070-2075, March 15, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity

Steven J. Kridel1, Fumiko Axelrod1, Natasha Rozenkrantz2 and Jeffrey W. Smith1

1 Cancer Research Center, The Burnham Institute, and 2 Activx Biosciences, La Jolla, California

One of the fundamental principles of pharmacology is that most drugs have side effects. Although considerable attention is paid to detrimental side effects, drugs can also have beneficial side effects. Given the time and expense of drug development, it would be particularly exciting if a systematic method could be applied to reveal all of the activities, including the unappreciated actions, of a potential drug. The present study takes the first step along this path. An activity-based proteomics strategy was used to simultaneously identify targets and screen for their inhibitors in prostate cancer. Orlistat, a Food and Drug Administration-approved drug used for treating obesity, was included in this screen. Surprisingly, we find a new molecular target and a potential new application for Orlistat. Orlistat is a novel inhibitor of the thioesterase domain of fatty acid synthase, an enzyme strongly linked to tumor progression. By virtue of its ability to inhibit fatty acid synthase, Orlistat halts tumor cell proliferation, induces tumor cell apoptosis, and inhibits the growth of PC-3 tumors in nude mice.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
S. M. Ueda, T.-L. Mao, F. P. Kuhajda, C. Vasoontara, R. L. Giuntoli, R. E. Bristow, R. J. Kurman, and I.-M. Shih
Trophoblastic Neoplasms Express Fatty Acid Synthase, Which May Be a Therapeutic Target via Its Inhibitor C93
Am. J. Pathol., December 1, 2009; 175(6): 2618 - 2624.
[Abstract] [Full Text] [PDF]

Home page
 J. Bacteriol.Home page
K. L. Low, P. S. S. Rao, G. Shui, A. K. Bendt, K. Pethe, T. Dick, and M. R. Wenk
Triacylglycerol Utilization Is Required for Regrowth of In Vitro Hypoxic Nonreplicating Mycobacterium bovis Bacillus Calmette-Guerin
J. Bacteriol., August 15, 2009; 191(16): 5037 - 5043.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. D. Green, D. B. Jump, and L. K. Olson
Elevated Insulin Secretion from Liver X Receptor-Activated Pancreatic {beta}-Cells Involves Increased de Novo Lipid Synthesis and Triacylglyceride Turnover
Endocrinology, June 1, 2009; 150(6): 2637 - 2645.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. Migita, S. Ruiz, A. Fornari, M. Fiorentino, C. Priolo, G. Zadra, F. Inazuka, C. Grisanzio, E. Palescandolo, E. Shin, et al.
Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer
J Natl Cancer Inst, April 1, 2009; 101(7): 519 - 532.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Ogino, K. Nosho, J. A. Meyerhardt, G. J. Kirkner, A. T. Chan, T. Kawasaki, E. L. Giovannucci, M. Loda, and C. S. Fuchs
Cohort Study of Fatty Acid Synthase Expression and Patient Survival in Colon Cancer
J. Clin. Oncol., December 10, 2008; 26(35): 5713 - 5720.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. L. Little, F. B. Wheeler, C. Koumenis, and S. J. Kridel
Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death
Mol. Cancer Ther., December 1, 2008; 7(12): 3816 - 3824.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. M. Knowles, C. Yang, A. Osterman, and J. W. Smith
Inhibition of Fatty-acid Synthase Induces Caspase-8-mediated Tumor Cell Apoptosis by Up-regulating DDIT4
J. Biol. Chem., November 14, 2008; 283(46): 31378 - 31384.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Migita, T. Narita, K. Nomura, E. Miyagi, F. Inazuka, M. Matsuura, M. Ushijima, T. Mashima, H. Seimiya, Y. Satoh, et al.
ATP Citrate Lyase: Activation and Therapeutic Implications in Non-Small Cell Lung Cancer
Cancer Res., October 15, 2008; 68(20): 8547 - 8554.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Prentki and S. R. M. Madiraju
Glycerolipid Metabolism and Signaling in Health and Disease
Endocr. Rev., October 1, 2008; 29(6): 647 - 676.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Zhan, N. Ginanni, M. R. Tota, M. Wu, N. W. Bays, V. M. Richon, N. E. Kohl, E. S. Bachman, P. R. Strack, and S. Krauss
Control of Cell Growth and Survival by Enzymes of the Fatty Acid Synthesis Pathway in HCT-116 Colon Cancer Cells
Clin. Cancer Res., September 15, 2008; 14(18): 5735 - 5742.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Ross, A. M. Najjar, M. Sankaranarayanapillai, W. P. Tong, K. Kaluarachchi, and S. M. Ronen
Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine
Mol. Cancer Ther., August 1, 2008; 7(8): 2556 - 2565.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
C. A. Haynes, J. C. Allegood, K. Sims, E. W. Wang, M. C. Sullards, and A. H. Merrill Jr.
Quantitation of fatty acyl-coenzyme As in mammalian cells by liquid chromatography-electrospray ionization tandem mass spectrometry
J. Lipid Res., May 1, 2008; 49(5): 1113 - 1125.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Liu, Y. Liu, and J.-T. Zhang
A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction
Mol. Cancer Ther., February 1, 2008; 7(2): 263 - 270.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. L. Vavere, S. J. Kridel, F. B. Wheeler, and J. S. Lewis
1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer
J. Nucl. Med., February 1, 2008; 49(2): 327 - 334.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Orita, J. Coulter, C. Lemmon, E. Tully, A. Vadlamudi, S. M. Medghalchi, F. P. Kuhajda, and E. Gabrielson
Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment
Clin. Cancer Res., December 1, 2007; 13(23): 7139 - 7145.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Beckers, S. Organe, L. Timmermans, K. Scheys, A. Peeters, K. Brusselmans, G. Verhoeven, and J. V. Swinnen
Chemical Inhibition of Acetyl-CoA Carboxylase Induces Growth Arrest and Cytotoxicity Selectively in Cancer Cells
Cancer Res., September 1, 2007; 67(17): 8180 - 8187.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. D. Richardson and J. W. Smith
Novel antagonists of the thioesterase domain of human fatty acid synthase
Mol. Cancer Ther., July 1, 2007; 6(7): 2120 - 2126.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
J. G. Pan and T. W. Mak
Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era?
Sci. Signal., April 10, 2007; 2007(381): pe14 - pe14.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. L. Little, F. B. Wheeler, D. R. Fels, C. Koumenis, and S. J. Kridel
Inhibition of Fatty Acid Synthase Induces Endoplasmic Reticulum Stress in Tumor Cells
Cancer Res., February 1, 2007; 67(3): 1262 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
C. D. Browne, E. J. Hindmarsh, and J. W. Smith
Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor
FASEB J, October 1, 2006; 20(12): 2027 - 2035.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
W. B. Kinlaw, J. L. Quinn, W. A. Wells, C. Roser-Jones, and J. T. Moncur
Spot 14: A Marker of Aggressive Breast Cancer and a Potential Therapeutic Target
Endocrinology, September 1, 2006; 147(9): 4048 - 4055.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. A. Madsen, E. I. Deryugina, S. Niessen, B. F. Cravatt, and J. P. Quigley
Activity-based Protein Profiling Implicates Urokinase Activation as a Key Step in Human Fibrosarcoma Intravasation
J. Biol. Chem., June 9, 2006; 281(23): 15997 - 16005.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X. Liu, Y. Shi, V. L. Giranda, and Y. Luo
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis.
Mol. Cancer Ther., March 1, 2006; 5(3): 494 - 501.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R.-C. Jiang, H.-D. Qin, M.-S. Zeng, W. Huang, B.-J. Feng, F. Zhang, H.-K. Chen, W.-H. Jia, L.-Z. Chen, Q.-S. Feng, et al.
A Functional Variant in the Transcriptional Regulatory Region of Gene LOC344967 Cosegregates with Disease Phenotype in Familial Nasopharyngeal Carcinoma
Cancer Res., January 15, 2006; 66(2): 693 - 700.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Brusselmans, E. De Schrijver, G. Verhoeven, and J. V. Swinnen
RNA Interference-Mediated Silencing of the Acetyl-CoA-Carboxylase-{alpha} Gene Induces Growth Inhibition and Apoptosis of Prostate Cancer Cells
Cancer Res., August 1, 2005; 65(15): 6719 - 6725.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. A. Menendez, L. Vellon, and R. Lupu
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene
Ann. Onc., August 1, 2005; 16(8): 1253 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Exp Biol MedHome page
J. A. Menendez, L. Vellon, and R. Lupu
Orlistat: From Antiobesity Drug to Anticancer Agent in Her-2/neu (erbB-2)-Overexpressing Gastrointestinal Tumors?
Exp Biol Med, March 1, 2005; 230(3): 151 - 154.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. Chakravarty, Z. Gu, S. S. Chirala, S. J. Wakil, and F. A. Quiocho
Human fatty acid synthase: Structure and substrate selectivity of the thioesterase domain
PNAS, November 2, 2004; 101(44): 15567 - 15572.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. M. Knowles, F. Axelrod, C. D. Browne, and J. W. Smith
A Fatty Acid Synthase Blockade Induces Tumor Cell-cycle Arrest by Down-regulating Skp2
J. Biol. Chem., July 16, 2004; 279(29): 30540 - 30545.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.